Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. 1996

V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
INSERM U75, CHU-Necker, Université René Descartes, Paris, France.

CYP2E1 is involved in the activation of various carcinogens, including N-nitrosamines, which are believed to be important in human carcinogenesis. Humans exhibit wide interindividual variability in levels of CYP2E1 mRNA and protein, which might explain interindividual differences in susceptibility to carcinogens activated by CYP2E1. Such variability could be due either to genetic polymorphisms observed in the CYP2E1 gene (Rsa I in the 5'-flanking region, Dra I in intron 6 and Taq I in intron 7) or to varying inducibility by xenobiotics. The aim of the present study was to establish whether, in a Caucasian population (n = 93), there existed a relationship between allelic forms of the CYP2E1 gene and the phenotype determined in vitro by hepatic ability to 6-hydroxylate chlorzoxazone. Rates of chlorzoxazone-6-hydroxylation were significantly correlated with levels of immunochemically measured CYP2E1 (p < 0.001). CYP1A2, 2C8, 2C9, 2C18, 2D6, 3A4 and 3A5 did not appear to be significantly involved in chlorzoxazone metabolism, whereas the participation of CYP1A1 could not be excluded. Frequencies of the rare alleles for the three polymorphism sites were 2.2% for RsaI, 7.5% for DraI and 8.5% for TaqI. Despite substantial interindividual variations in chlorzoxazone hydroxylase activity, no relationship between any of the three polymorphisms and CYP2E1 activity was established. Therefore, in humans, interindividual variability in CYP2E1 levels is probably due to differing induction levels as a result of environmental factors, or to genetic factors other than those studied in this work.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002753 Chlorzoxazone A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) Paraflex,Parafon,Parafon Forte DSC
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D019392 Cytochrome P-450 CYP2E1 An ethanol-inducible cytochrome P450 enzyme that metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Substrates include ETHANOL; INHALATION ANESTHETICS; BENZENE; ACETAMINOPHEN and other low molecular weight compounds. CYP2E1 has been used as an enzyme marker in the study of alcohol abuse. 4-Nitrophenol-2-Hydroxylase,CYP2E1,Dimethylnitrosamine N-Demethylase,CYP 2E1,CYP IIE1,CYPIIE1,Cytochrome P-450 (ALC),Cytochrome P-450 IIE1,Cytochrome P-450-J,Cytochrome P450 2E1,N-Nitrosodimethylamine Demethylase,4 Nitrophenol 2 Hydroxylase,Cytochrome P 450 CYP2E1,Cytochrome P 450 IIE1,Cytochrome P 450 J,Dimethylnitrosamine N Demethylase,N Nitrosodimethylamine Demethylase

Related Publications

V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
January 2020, Xenobiotica; the fate of foreign compounds in biological systems,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
August 1999, Biochemical pharmacology,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
April 2003, Hepatology (Baltimore, Md.),
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
January 1996, Methods in enzymology,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
August 2002, Drug metabolism and disposition: the biological fate of chemicals,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
November 2013, Breast cancer research : BCR,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
April 2001, The Journal of biological chemistry,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
September 1996, Chemical research in toxicology,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
January 1996, Chemical research in toxicology,
V Carrière, and F Berthou, and S Baird, and C Belloc, and P Beaune, and I de Waziers
June 2005, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!